Quest Diagnostics Price Target Lowered to $55.00 at Canaccord Genuity (DGX)
Stock analysts at Canaccord Genuity decreased their target price on shares of Quest Diagnostics (NYSE:DGX) from $59.00 to $55.00 in a report issued on Friday, AR Network reports. The firm currently has a “hold” rating on the stock. Canaccord Genuity’s target price would suggest a potential downside of 5.04% from the company’s current price.
A number of other firms have also recently commented on DGX. Analysts at Mizuho cut their price target on shares of Quest Diagnostics from $62.00 to $58.00 in a research note to investors on Thursday. They now have a “neutral” rating on the stock. Separately, analysts at Citigroup Inc. reiterated a “neutral” rating on shares of Quest Diagnostics in a research note to investors on Friday, October 11th. They now have a $60.00 price target on the stock, down previously from $64.00. Finally, analysts at Wells Fargo & Co. reiterated a “market perform” rating on shares of Quest Diagnostics in a research note to investors on Thursday, October 10th. Two research analysts have rated the stock with a sell rating, twelve have given a hold rating and five have assigned a buy rating to the company’s stock. Quest Diagnostics presently has an average rating of “Hold” and an average price target of $60.81.
Shares of Quest Diagnostics (NYSE:DGX) traded down 1.66% on Friday, hitting $57.92. 2,262,925 shares of the company’s stock traded hands. Quest Diagnostics has a one year low of $55.16 and a one year high of $63.40. The stock’s 50-day moving average is $60.93 and its 200-day moving average is $59.79. The company has a market cap of $8.797 billion and a price-to-earnings ratio of 17.97.
Quest Diagnostics (NYSE:DGX) last issued its quarterly earnings data on Thursday, October 17th. The company reported $1.02 earnings per share for the quarter, missing the analysts’ consensus estimate of $1.20 by $0.18. The company had revenue of $1.79 billion for the quarter, compared to the consensus estimate of $1.84 billion. During the same quarter last year, the company posted $1.18 earnings per share. Quest Diagnostics’s revenue was down 1.9% compared to the same quarter last year. Analysts expect that Quest Diagnostics will post $4.23 EPS for the current fiscal year.
Quest Diagnostics Incorporated (NYSE:DGX)is a provider of diagnostic testing, information and services, providing insights that enable patients and physicians to make healthcare decisions.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.